Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy

NCT01741909 | Withdrawn

• 1 other identifier: EMC-85-12-CTIL
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Intravenous Azythromycin therapy is considerably more expensive than oral therapy. The investigators believe that intravenous therapy is prolonged more that necessary and that oral therapy can be used much earlier in the course of the disease. The investigators plan to check if that statement is true and intervene in order to shorten the intravenous therapy.

Conditions

Pneumonia

Keywords

azythromycin; community acquired pneumonia; intravenous; oral

Outcome Measures

Primary Outcomes (1)

• length of intravenous azythromycin treatment

  6 months

Study Arms (1)

Before, After

EXPERIMENTAL

The intervention is educational

Behavioral: education

Interventions

education BEHAVIORAL

after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment

Before, After

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients hospitalized with community acquired pneumonia treated by azythromycin

You may not qualify if:

• Age under 18

Sponsors & Collaborators

• HaEmek Medical Center, Israel: lead

Study Sites (1)

Haemek Medical Center

Afula, Israel

Location

MeSH Terms

Conditions

Pneumonia; Community-Acquired Pneumonia

Interventions

Educational Status

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Lung Diseases; Respiratory Tract Diseases; Community-Acquired Infections

Intervention Hierarchy (Ancestors)

Socioeconomic Factors; Population Characteristics

Study Officials

• Lee H Goldstein, MD

  haemek medical center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lee Goldstein MD

Study Record Dates

• First Submitted: December 2, 2012
• First Posted: December 5, 2012
• Study Start: December 1, 2012
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: August 31, 2016

Record last verified: 2016-08

Locations

IL (1)